
Teva vice chairman quits
pharmafile | December 17, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Teva, amir elstein, moshe manyÂ
Teva Pharmaceuticals vice chairman Professor Moshe Many has requested to leave the firm at the end of this month for personal reasons.
Many will remain a member of Teva’s board of directors but his role is to be filled by Amir Elstein (pictured), who has been appointed to replace Many from next year.
“I would like to thank Prof. Many for his outstanding service as vice chairman and wish Amir success in continuing Moshe’s good work,” said Teva chairman, Dr Phillip Frost.
Related Content

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …






